STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry is “not prepared for the next wave of biotech innovation.”
His report ends on a somewhat dismal note: the industry is long on diagnosis (clinical development is too expensive) and short on cures.
Click this link for the original source of this article.
Author: Brian Finrow and Aleks Engel and Srinivas Akkaraju
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
